AGÕæÈ˹ٷ½

STOCK TITAN

[8-K] Ventyx Biosciences, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

On 7 Aug 2025, XWELL, Inc. (Nasdaq: XWEL) filed an 8-K announcing it has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its shares maintained a closing bid of � $1.00 for 16 consecutive business days (16 Jul � 6 Aug 2025). Nasdaq’s Listing Qualifications Department confirmed the requirement is satisfied and the prior 13 May 2025 non-compliance notice is now closed.

The filing contains no financial results, guidance, or operational updates; it solely removes the delisting overhang tied to the minimum-price deficiency. The resolution improves listing certainty but does not alter underlying fundamentals.

Il 7 agosto 2025, XWELL, Inc. (Nasdaq: XWEL) ha presentato un modulo 8-K annunciando di aver ripristinato la conformità con la Regola di Quotazione Nasdaq 5550(a)(2), dopo che le sue azioni hanno mantenuto un prezzo di chiusura pari o superiore a $1,00 per 16 giorni lavorativi consecutivi (dal 16 luglio al 6 agosto 2025). Il Dipartimento per le Qualifiche di Quotazione di Nasdaq ha confermato che il requisito è stato soddisfatto e che la precedente comunicazione di non conformità del 13 maggio 2025 è ora chiusa.

La comunicazione non contiene risultati finanziari, previsioni o aggiornamenti operativi; si limita a rimuovere la minaccia di esclusione legata alla carenza del prezzo minimo. La risoluzione aumenta la certezza della quotazione ma non modifica i fondamentali sottostanti.

El 7 de agosto de 2025, XWELL, Inc. (Nasdaq: XWEL) presentó un formulario 8-K anunciando que ha recuperado el cumplimiento con la Regla de Cotización Nasdaq 5550(a)(2) después de que sus acciones mantuvieran un precio de cierre de al menos $1.00 durante 16 días hábiles consecutivos (del 16 de julio al 6 de agosto de 2025). El Departamento de Calificaciones de Cotización de Nasdaq confirmó que se cumple el requisito y que la notificación previa de incumplimiento del 13 de mayo de 2025 ha sido cerrada.

La presentación no incluye resultados financieros, pronósticos ni actualizaciones operativas; únicamente elimina la amenaza de exclusión relacionada con la deficiencia del precio mínimo. La resolución mejora la certeza de la cotización pero no altera los fundamentos subyacentes.

2025ë…� 8ì›� 7ì�, XWELL, Inc. (나스ë‹�: XWEL)ëŠ� 8-K 보고서를 제출하며, 16거래ì� ì—°ì†(2025ë…� 7ì›� 16ì¼~8ì›� 6ì�) 종가가 $1.00 ì´ìƒì� 유지하여 나스ë‹� ìƒìž¥ 규칙 5550(a)(2)ì—� 재ì Çê�했다ê³� 발표했습니다. 나스ë‹� ìƒìž¥ ìžê²© 부서는 요건 충족ì� 확ì¸í–ˆìœ¼ë©�, 2025ë…� 5ì›� 13ì¼ì— 발행ë� 비ì í•� 통지ëŠ� ì´ì œ 종료ë˜ì—ˆìŠµë‹ˆë‹�.

ì´ë²ˆ 보고서ì—ëŠ� 재무 실ì , ì „ë§, ìš´ì˜ ì—…ë°ì´íŠ¸ê°€ í¬í•¨ë˜ì–´ 있지 않으ë©�, 단지 최저 ê°€ê²� 미달ë¡� ì¸í•œ ìƒìž¥ íì§€ 위험ì� 해소하는 내용입니ë‹�. ì� í•´ê²°ì±…ì€ ìƒìž¥ ì•ˆì •ì„±ì„ ë†’ì´ì§€ë§� 근본ì ì¸ 사항ì—는 ë³€í•¨ì´ ì—†ìŠµë‹ˆë‹¤.

Le 7 août 2025, XWELL, Inc. (Nasdaq : XWEL) a déposé un formulaire 8-K annonçant avoir retrouvé la conformité avec la règle de cotation Nasdaq 5550(a)(2) après que ses actions ont maintenu un cours de clôture � 1,00 $ pendant 16 jours ouvrables consécutifs (du 16 juillet au 6 août 2025). Le département des qualifications de cotation de Nasdaq a confirmé que l’exigence est satisfaite et que l’avis de non-conformité antérieur du 13 mai 2025 est désormais clos.

Le dépôt ne contient aucun résultat financier, prévisions ou mise à jour opérationnelle ; il supprime uniquement la menace de radiation liée au défaut de prix minimum. Cette résolution améliore la certitude de la cotation mais ne modifie pas les fondamentaux sous-jacents.

Am 7. August 2025 reichte XWELL, Inc. (Nasdaq: XWEL) ein 8-K-Formular ein und gab bekannt, dass das Unternehmen die Einhaltung der Nasdaq-Listing-Regel 5550(a)(2) wiedererlangt hat, nachdem die Aktien an 16 aufeinanderfolgenden Handelstagen (16. Juli bis 6. August 2025) einen Schlusskurs von mindestens $1,00 gehalten hatten. Die Abteilung für Notierungsqualifikationen der Nasdaq bestätigte, dass die Anforderung erfüllt ist und die frühere Nichtkonformitätsmitteilung vom 13. Mai 2025 nun geschlossen wurde.

Die Einreichung enthält keine finanziellen Ergebnisse, Prognosen oder operative Updates; sie beseitigt ausschließlich die drohende Delistung aufgrund des Mindestkursmangels. Die Lösung erhöht die Listing-Sicherheit, ändert jedoch nicht die zugrunde liegenden Fundamentaldaten.

Positive
  • Nasdaq compliance restored, removing immediate delisting threat and potential negative sentiment.
Negative
  • None.

Insights

TL;DR: Delisting risk lifted; modestly positive for sentiment, fundamentals unchanged.

Regaining Nasdaq compliance eliminates an overhang that can depress liquidity and deter institutional investors. While no cash-flow or earnings data changed, maintaining a national market listing preserves access to capital and trading volumes. Given the swift resolution (within 3 months of notice), management avoided more dilutive remedies such as a reverse split. Impact is positive, though largely cosmetic unless the share price holds organically above $1.00.

Il 7 agosto 2025, XWELL, Inc. (Nasdaq: XWEL) ha presentato un modulo 8-K annunciando di aver ripristinato la conformità con la Regola di Quotazione Nasdaq 5550(a)(2), dopo che le sue azioni hanno mantenuto un prezzo di chiusura pari o superiore a $1,00 per 16 giorni lavorativi consecutivi (dal 16 luglio al 6 agosto 2025). Il Dipartimento per le Qualifiche di Quotazione di Nasdaq ha confermato che il requisito è stato soddisfatto e che la precedente comunicazione di non conformità del 13 maggio 2025 è ora chiusa.

La comunicazione non contiene risultati finanziari, previsioni o aggiornamenti operativi; si limita a rimuovere la minaccia di esclusione legata alla carenza del prezzo minimo. La risoluzione aumenta la certezza della quotazione ma non modifica i fondamentali sottostanti.

El 7 de agosto de 2025, XWELL, Inc. (Nasdaq: XWEL) presentó un formulario 8-K anunciando que ha recuperado el cumplimiento con la Regla de Cotización Nasdaq 5550(a)(2) después de que sus acciones mantuvieran un precio de cierre de al menos $1.00 durante 16 días hábiles consecutivos (del 16 de julio al 6 de agosto de 2025). El Departamento de Calificaciones de Cotización de Nasdaq confirmó que se cumple el requisito y que la notificación previa de incumplimiento del 13 de mayo de 2025 ha sido cerrada.

La presentación no incluye resultados financieros, pronósticos ni actualizaciones operativas; únicamente elimina la amenaza de exclusión relacionada con la deficiencia del precio mínimo. La resolución mejora la certeza de la cotización pero no altera los fundamentos subyacentes.

2025ë…� 8ì›� 7ì�, XWELL, Inc. (나스ë‹�: XWEL)ëŠ� 8-K 보고서를 제출하며, 16거래ì� ì—°ì†(2025ë…� 7ì›� 16ì¼~8ì›� 6ì�) 종가가 $1.00 ì´ìƒì� 유지하여 나스ë‹� ìƒìž¥ 규칙 5550(a)(2)ì—� 재ì Çê�했다ê³� 발표했습니다. 나스ë‹� ìƒìž¥ ìžê²© 부서는 요건 충족ì� 확ì¸í–ˆìœ¼ë©�, 2025ë…� 5ì›� 13ì¼ì— 발행ë� 비ì í•� 통지ëŠ� ì´ì œ 종료ë˜ì—ˆìŠµë‹ˆë‹�.

ì´ë²ˆ 보고서ì—ëŠ� 재무 실ì , ì „ë§, ìš´ì˜ ì—…ë°ì´íŠ¸ê°€ í¬í•¨ë˜ì–´ 있지 않으ë©�, 단지 최저 ê°€ê²� 미달ë¡� ì¸í•œ ìƒìž¥ íì§€ 위험ì� 해소하는 내용입니ë‹�. ì� í•´ê²°ì±…ì€ ìƒìž¥ ì•ˆì •ì„±ì„ ë†’ì´ì§€ë§� 근본ì ì¸ 사항ì—는 ë³€í•¨ì´ ì—†ìŠµë‹ˆë‹¤.

Le 7 août 2025, XWELL, Inc. (Nasdaq : XWEL) a déposé un formulaire 8-K annonçant avoir retrouvé la conformité avec la règle de cotation Nasdaq 5550(a)(2) après que ses actions ont maintenu un cours de clôture � 1,00 $ pendant 16 jours ouvrables consécutifs (du 16 juillet au 6 août 2025). Le département des qualifications de cotation de Nasdaq a confirmé que l’exigence est satisfaite et que l’avis de non-conformité antérieur du 13 mai 2025 est désormais clos.

Le dépôt ne contient aucun résultat financier, prévisions ou mise à jour opérationnelle ; il supprime uniquement la menace de radiation liée au défaut de prix minimum. Cette résolution améliore la certitude de la cotation mais ne modifie pas les fondamentaux sous-jacents.

Am 7. August 2025 reichte XWELL, Inc. (Nasdaq: XWEL) ein 8-K-Formular ein und gab bekannt, dass das Unternehmen die Einhaltung der Nasdaq-Listing-Regel 5550(a)(2) wiedererlangt hat, nachdem die Aktien an 16 aufeinanderfolgenden Handelstagen (16. Juli bis 6. August 2025) einen Schlusskurs von mindestens $1,00 gehalten hatten. Die Abteilung für Notierungsqualifikationen der Nasdaq bestätigte, dass die Anforderung erfüllt ist und die frühere Nichtkonformitätsmitteilung vom 13. Mai 2025 nun geschlossen wurde.

Die Einreichung enthält keine finanziellen Ergebnisse, Prognosen oder operative Updates; sie beseitigt ausschließlich die drohende Delistung aufgrund des Mindestkursmangels. Die Lösung erhöht die Listing-Sicherheit, ändert jedoch nicht die zugrunde liegenden Fundamentaldaten.

false000185119400018511942025-08-072025-08-07

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 07, 2025

 

 

VENTYX BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40928

83-2996852

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

12790 El Camino AGÕæÈ˹ٷ½

Suite 200

 

San Diego, California

 

92130

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 760 407-6511

 

 

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

VTYX

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 2.02 Results of Operations and Financial Condition.

On August 7, 2025, Ventyx Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Current Report on Form 8-K shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.

 

Description

 

 

 

99.1

 

Press Release, dated August 7, 2025

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

VENTYX BIOSCIENCES, INC.

 

 

 

 

Date:

August 7, 2025

By:

/s/ Raju Mohan

 

 

 

Raju Mohan, Ph.D.
Chief Executive Officer and Director
(Principal Executive Officer)

 


FAQ

Why did XWELL (XWEL) file this 8-K?

To disclose that Nasdaq confirmed the company has met the $1.00 minimum bid requirement and the deficiency matter is closed.

What period satisfied the bid-price rule for XWEL?

16 consecutive business days from 16 Jul 2025 to 6 Aug 2025.

Was a reverse stock split required to regain compliance?

No. XWELL met the rule through market trading; the 8-K mentions no corporate actions.

Does the filing include earnings or revenue figures?

No financial performance data is included; the report is limited to listing status.

Is the Nasdaq compliance issue now fully resolved for XWEL?

Yes. Nasdaq stated the matter is closed in its 7 Aug 2025 letter.
Ventyx Biosciences, Inc.

NASDAQ:VTYX

VTYX Rankings

VTYX Latest News

VTYX Latest SEC Filings

VTYX Stock Data

183.60M
68.23M
4.12%
74.35%
6.98%
Biotechnology
Pharmaceutical Preparations
United States
SAN DIEGO